Floatz logo

Saroglitazar

NAFLD

Zydus Lifesciences LimitedSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
81/ 100

Competitive context

139 Active assets in the NAFLD cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB

View all 50 →

Same molecule, other indications

Saroglitazar is also rated in:

primary biliary cholangitisDormant
BB
Indicative ·
71 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
66 / 100
View asset →
inherited lipid metabolism disorderDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →